Successful vaccination for Lyme disease:a novel mechanism

Bibliography

• JOHNSON R, SCHMID G, HYDE F et al.:Borreliaburg-v dorferisp.nov.:etiologicagentofLymedisease.Int. J. Systemic Bacteriol(1984) 34:496–497.
   Google Scholar
• •The original paper reporting B. burgdorferias the agent of Lyme disease.
   Google Scholar
• WALLICH R, KRAMER M, SIMON M: Therecombinant outersurfaceproteinA(lipOspA)ofBorreliaburgdor-feri:aLymediseasevaccine.Infection(1996) 24:396–397.
   Google Scholar
• CENTERS FOR DISEASE CONTROL AND PREVENTION: Summary of notifiable diseases - United States 1996. MMWR(1997).
   Google Scholar
• EDELMAN R: Perspectiveonthedevelopmentofvac-cinesagainstLymedisease.Vaccine(1991) 9:531–532.
   PubMed Web of Science ®Google Scholar
• YOUNG J: Correspondence:underreportingofLymedisease.New Engl. J. Med.(1998) 338:1629.
   Google Scholar
• EVANS J: Lymedisease.Curr. Opin. Rheumatol.(1996) 8:327–333.
   PubMedGoogle Scholar
• CENTERS FOR DISEASE CONTROL AND PREVENTION: Casedefinitionsforpublichealthsurveillance.MMWR(1990) 39:19.
   Google Scholar
• TELFORD S, FIKRIG E: ProgresstowardsavaccineforLymedisease.Clin. Immun.(1995) 4:49–60.
   Web of Science ®Google Scholar
• •A review summarising experimental studies leading to vac-cine development.
   Google Scholar
• BARANTON G, POSTIC D, SAINT GIRONS I et al:Delinea-tionofBorreliaburgdorferisensustricto,Borreliagariniisp.nov.,andgroupV5461associatedwithLymeborreliosis.Int. J. Syst. Bacteriol(1992) 42:378–83.
   Google Scholar
• JOHNSON R, KODNER C, RUSSELL M: Passiveimmunisa-tion of hamsters against experimental infection with Lymediseasespirochete.Infect. Immun.(1986) 53:713–714.
   PubMed Web of Science ®Google Scholar
• ••Syrian hamsters are successfully protected against challengewith strains of B. burgdorferi.
   Google Scholar
• JOHNSON R, KODNER C, RUSSELL M: Activeimmunisa- tionof hamsters against experimental infection with Borreliaburgdorferi.Infect. Immun.(1986) 54:897–898.
   PubMed Web of Science ®Google Scholar
• ••A single dose of an inactivated whole cell vaccine confersimmunity in hamsters.
   Google Scholar
• CHU H, CHAVEZ L, BLUMER B et al:Immunogenicity andefficacystudyofcommercialBorreliaburgdor-feribacterin.J. Am. Vet. Med. Assoc.(1992) 201:403–411.
   PubMed Web of Science ®Google Scholar
• SCHMITZ J, SCHELL R, HEJKA A et al.:Passiveimmunisa-tion prevents induction of Lyme arthritis in LSH ham-sters.Infect. Immun.(1990) 58:144–148.
   PubMed Web of Science ®Google Scholar
• LENGL-JANSSEN B, STRAUSS A, STEERE A et al:TheThelper cell response in Lyme arthritis: differential rec-ognitionofBorreliaburgdorferioutersurfaceproteinA in patients with treatment-resistant or treatment-responsiveLymearthritis.J. Exp. Med.(1994) 180:2069–2078.
   PubMed Web of Science ®Google Scholar
• KALISH R, LEONG J, STEERE A: Associationoftreatment-resistant chronic Lyme arthritis with HLA-DR4andantibodyreactivitytoOspAandOspBofBor-reliaburgdorferi.Infect. Immun.(1993) 61:2774–2779.
   PubMed Web of Science ®Google Scholar
• ABERER E, BRUNNER C, SUCHANEK G et al.:Molecularmimicry and Lyme borreliosis: a shared antigenic de-terminantbetweenBorreliaburgdorferiandhumantissue.Ann. NeuroL(1989) 26:732–737.
   PubMed Web of Science ®Google Scholar
• SIGAL L: Cross-reactivitybetweenBorreliaburgdor-feriflagellinandahumanaxonal64,000molecularweightprotein.J. Infect. Dis.(1993) 167:1372–1378.
   Google Scholar
• STEERE A: Lymedisease.New EngL J. Med.(1989) 321:586–96.
   Web of Science ®Google Scholar
• CRAFT J, FISCHER D, SHIMAMOTO G et al:AntigensofBorreliaburgdorferirecognisedduringLymedisease:appearance of a new immunoglobulin M response and expansion of the immunoglobulin G response late in theillness.J. Clin. Invest.(1986) 78:934–939.
   PubMed Web of Science ®Google Scholar
• FRASER C, CASJENS S, HUANG W et al:Genomicse-quenceofaLymediseasespirochete,Borreliaburg-dorferi.Nature(1997) 390:580–586.
   PubMed Web of Science ®Google Scholar
• BARTHOLD S, PERSING D, ARMSTRONG A et al.:KineticsofBorreliaburgdorferidisseminationandevolutionofdiseaseafterintradermalinoculationofmice.Am. J. Pathol.(1991) 139:263–273.
   PubMed Web of Science ®Google Scholar
• DATTWYLER R, VOLKMAN D, LUFT B et al.:SeronegativeLyme disease. Dissociation of specific T- and B-lymphocyteresponsestoBorreliaburgdorferi.New Engl. J. Med.(1988) 319:1441–1446.
   PubMed Web of Science ®Google Scholar
• SZCZEPANSKI A, BENACH J: Lymeborreliosis:hostre-sponsestoBorreliaburgdorferi.Microbiol. Rev.(1991) 55:21–34.
   PubMedGoogle Scholar
• AYDINTUG M, GU K, PHILLIPP M: Borreliaburgdorferiantigens that are targeted by antibody dependent, complement-mediated killing in the rhesus monkey. Infect. Immun.(1994) 62:4929–4937.
   PubMed Web of Science ®Google Scholar
• GREENE R, WALKER R, NICHOLSON W et al.:Im-munoblot analysis of immunoglobulin G to the Lyme diseaseagent(Borreliaburgdorferi)inexperimen-tallyandnaturallyinfecteddogs.J. Clin. Microbiol.(1988) 26:648–653.
   PubMed Web of Science ®Google Scholar
• GERN L, SCHIABLE L, SIMON M: LymediseaseagentBor-reliaburgdorferiinfluencesinfectionandimmunere-sponsesininbredstrainsofmice.J. Infect. Dis.(1993) 167:971–75.
   PubMed Web of Science ®Google Scholar
• KURTENBACH K, DIZIJ A, SEITZ HM et al:DifferentialimmuneresponsestoBorreliaburgdorferiin Europeanwild rodent species influence spirochete transmissiontoIxodesricinusL.(Acari:Ixodidae).In-fect. Immun.(1994) 62(12):5344–5352.
   Google Scholar
• KURTENBACH K, DIZIJ A, VOET P, HAUSER P, SIMON MM:Vaccination of natural reservoir hosts with recombi-nant lipidated OspA induces a transmission-blocking immunity against Lyme disease spirochaetes associ-ated with high levels of LA-2 equivalent antibodies. Vaccine(1997) 15(15):1670–1674.
   PubMed Web of Science ®Google Scholar
• ROEHRIG J, PIESMAN J, HUNT A et al.:Thehamsterim-muneresponsetotick-transmittedBorreliaburgdor-feridiffersfromthersponsetoneedle-inoculated,culturedorganisms.J. Immunol(1992) 149:3648–3653.
   PubMed Web of Science ®Google Scholar
• BARTHOLD S, FIKRIG E, BOCKENSTEDT L et al.:Circum-vention of outer surface protein A immunity by host-adaptedBorreliaburgdorferi.Infect. Immun.(1995) 63 :2255–2261.
   PubMed Web of Science ®Google Scholar
• SCHWAN T, PIESMAN J, GOLDE W et al:InductionofanoutersurfaceproteinonBorreliaburgdorferiduringfeeding.Proc. Natl. Acad. ScL USA(1995) 92:2909–2913.
   PubMed Web of Science ®Google Scholar
• DE SILVA A, TELFORD SI, BRUNET L et al.:Borreliaburg-dorferiOspAisanarthropod-specifictransmissionblockingLymediseasevaccine.J. Exp. Med.(1996) 183:271–275.
   PubMed Web of Science ®Google Scholar
• BARTHOLD S, BECK D, HANSEN G et al.:Lymeborrelio-sisinselectedstrainsandagesoflaboratorymice.J. In-fect. Dis.(1990) 162:133–138.
   PubMed Web of Science ®Google Scholar
• FIKRIGE, BARTHOLD S, KANTOR F et al.:Protectionofmice against the Lyme disease agent by immunizing withrecombinantOspA.Science(1990) 250:553-556. A recombinant OspA vaccine protects against Lyme disease in the mouse model.
   Google Scholar
• FIKRIGE, BARTHOLD S, KANTOR F et al.:Long-termpro-tection of mice from Lyme disease by vaccination with OspA.Infect. Immun.(1992) 60:773–777.
   PubMed Web of Science ®Google Scholar
• SCHAIBLE U, KRAMER M, EICKMANN K et al.:Monoclonal antibodiesspecificfortheOspAofBorreliaburgdor-feripreventLymeborreliosisinseverecombinedim-munodeficiencymice.Proc. Natl. Acad. Sci. USA(1990) 87:768–772.
   Web of Science ®Google Scholar
• LOVETICH S, GALLISTER S, DUCHATEAU B etal.:Abilities ofOspA proteins from different seroprotective groups ofBorreliaburgdorferitoprotecthamstersfromin-fection.Infect. Immun.(1995) 80:2113–2119.
   Google Scholar
• CHANG Y, APPEL M, JACOBSEN R et al.:Recombinant OspAprotects dogs from infection and disease caused byBorreliaburgdorferi.Infect. Immun.(1995) 63:3543–3549.
   PubMed Web of Science ®Google Scholar
• PHILLIPP M, LOBET Y, BOHNS RJ et al.:Safetyandimmu-nogenicity of recombinant outer-surface protein A (OspA)vaccineformulationsintherhesusmonkey.J. Spirochetal Tickborne Dis.(1990) 3:1–13.
   Google Scholar
• STEERE A, TAYLOR E, WILSON M et al.:Alongitudinalas-sessment of the clinical and epidemiologic features of Lymediseaseinadefinedpopulation.J. Infect. Dis.(1986) 154:295-300. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs(1999) 8(1)
   Google Scholar
• PAVIA C, KISSEL V, BITTKER S et al:Antiborrelialactivityof serum from rats injected with the Lyme disease spi-rochete.J. Infect. Dis.(1991) 163:656–659.
   PubMed Web of Science ®Google Scholar
• MONTGOMERY R, NATHANSON M, MALAWISTA S: Fcandnon-Fc-mediatedphagocytosisofBorreliaburgdor-feribymacrophages.J. Infect. Dis.(1994) 170:890–893.
   PubMed Web of Science ®Google Scholar
• ERDILE L, BRANDT M, WARAKOMSKI D et al.:Roleofat-tachedlipidinimmunogenicityofBorreliaburgdor-feriOspA.Infect. Immun.(1993) 61:81–90.
   PubMed Web of Science ®Google Scholar
• CHAMBERLAIN N, BRANDT M, ERWIN J et al.:Majorinte-gralmembraneproteinimmunogensofTreponemapallidumareproteolipids.Infect. Immun.(1989) 57:2872–2877.
   PubMed Web of Science ®Google Scholar
• FIKRIG E, TELFORD S, III, BARTHOLD S etal.:EliminationofBorreliaburgdorferifromvectorticksfeedingonOspA-immunisedmice.Proc. Natl. Acad. ScL USA(1992) 89:5418–5421.
   PubMed Web of Science ®Google Scholar
• KELLER D, KOSTER F, MARKS D et al.:Safetyandimmu- nogenicityof a recombinant outer surface protein A Lymevaccine.JAMA(1994) 271:1764–1768.
   Google Scholar
• •Report of the first Phase II clinical (safety and immunogenic-ity) trial for human Lyme disease vaccine.
   Google Scholar
• VAN HOECKE C, DEGROVE D, HANSEN P et al:Evalua-tion of three formulations of a candidate vaccine againstLymediseaseinhealthyadultvolunteers.VI In-ternational Conference on Lyme Borreliosis(1994) :#014M.
   Google Scholar
• MARKS D, HOSBACH P, KOSTER F et al:Clinicalstudiesin humans of outer surface protein A (OspA) vaccine forLymedisease.VI International Conference on Lyme Borreliosis(1994):#015.
   Google Scholar
• STEERE A, SIKAND V, PARENTI D et al:VaccinationforLymediseaseusingarecombinantBorrelia burgdorferioutersurfacelipoproteinAvaccine.New Engl. J. Med.(1998) 339:209–215.
   PubMed Web of Science ®Google Scholar
• ••Report of a Phase III clinical trial for human Lyme diseasevaccine.
   Google Scholar
• VAN HOECKE C, VOET P, DEGROVE D et al:Immuno- genicityof Al(OH)3-adsorbed and plain lipoprotein OspAvaccineformulationsinmonkeysandman.34th Intel-science Conference on Antimicrobial Agents and Che-motherapy(1994).
   Google Scholar
• CENTERS FOR DISEASE CONTROL AND PREVENTION: Lymedisease-UnitedStates1996.MMWR Morbidity and Mortality Weekly Report(1997) 46:531–535.
   PubMedGoogle Scholar
• SIGAL L, ZAHRADNIK J, LAVIN P et al.:Avaccineconsist-ingofrecombinantBorreliaburgdorferiouter-surfaceproteinAtopreventLymedisease.New Engl. J. Med.(1998) 339:216–222.
   PubMed Web of Science ®Google Scholar
• ••Report of a Phase III clinical trial for human Lyme diseasevaccine.
   Google Scholar
• SCHOEN R, FIKRIG E: Lymediseasevaccine.In: Current Statusin Lyme Disease.Rahn DW, Evans D (Eds.), American College of Physicians, Philadelphia (1998).
   Google Scholar
• ••Excellent, thorough review of Lyme disease and vaccine de-velopment to the Phase II human trials.
   Google Scholar
• WORMSER GP: Lymediseasevaccine.Infection(1996) 24:203–207.
   PubMed Web of Science ®Google Scholar
• •Review of Lyme disease progress toward vaccine development.
   Google Scholar